Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease

Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease

Abstract Chronic kidney disease affects ~10% of people worldwide and there are no disease modifying therapeutics that address the underlying cause of any form of kidney disease. Genome wide association studies have identified the G1 and G2 variants in the apolipoprotein L1 (APOL1) gene as major cont...

Full description

Saved in:
Bibliographic Details
Main Authors: Brandon Zimmerman, Leslie A. Dakin, Anne Fortier, Evanthia Nanou, Angelo Blasio, James Mann, Howard Miller, Marissa Fletcher, Tiansheng Wang, Suganthini Nanthakumar, Gizelle McCarthy, Caline Matar, Prachi Matsye, Guanyu Wang, Phillip Snyder, Kevin Daniel, Harsha Swamy, Kelly Sullivan, Franklin Bright, Audrey Powers, Kevin J. Gagnon, Fan Lu, Steven Paula, Suvarna Khare-Pandit, Larry Henry, Martine Hamel, Francois Denis, Olivier Nicolas, Niresh Hariparsad, Shyamesh Kumar, Jennifer Proctor, Timothy Senter, Brinley Furey, Mark E. Bunnage
Format: Article
Language:English
Published: Nature Portfolio 2025-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-55408-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-55408-2

Similar Items